SARS-CoV-2 Cell Entry Is Blocked by a Clinically Proven Protease Inhibitor
As described in their recent Cell study, Hoffmann et al. identified the serine protease TMPRSS2 as a critical factor in the priming of the SARS-CoV-2 spike protein with its receptor ACE2, and demonstrated that a clinically proven protease inhibitor, camostat mesylate, is able to interfere with SARS-CoV-2 infection of lung cells.
SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604)
SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid antibody [6H3] (GTX632269)
>> View article